published meta-analysis   sensitivity analysis   studies

sofosbuvir and daclatasvir in COVID 19 hospitalized - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsMobarak S (DISCOVER), 2021 1.10 [0.77; 1.57] 1.10[0.77; 1.57]Mobarak S (DISCOVER), 202110%1,083NAnot evaluable deathsdetailed resultsMobarak S (DISCOVER), 2021 1.15 [0.80; 1.67] Sadeghi , 2020 0.56 [0.12; 2.56] Yakoot, 2020 0.38 [0.07; 2.08] 0.97[0.58; 1.63]Mobarak S (DISCOVER), 2021, Sadeghi , 2020, Yakoot, 2020312%1,238moderatenot evaluable clinical improvement (14-day)detailed resultsSadeghi , 2020 3.63 [1.02; 12.93] 3.63[1.02; 12.93]Sadeghi , 202010%66NAnot evaluable mechanical ventilationdetailed resultsMobarak S (DISCOVER), 2021 1.52 [0.72; 3.19] Sadeghi , 2020 0.37 [0.09; 1.58] Yakoot, 2020 0.38 [0.07; 2.08] 0.73[0.25; 2.10]Mobarak S (DISCOVER), 2021, Sadeghi , 2020, Yakoot, 2020353%1,238moderatenot evaluable ICU admissiondetailed resultsYakoot, 2020 0.38 [0.07; 2.08] 0.38[0.07; 2.08]Yakoot, 202010%89NAnot evaluable recoverydetailed resultsMobarak S (DISCOVER), 2021 0.97 [0.89; 1.05] Yakoot, 2020 1.60 [1.00; 2.55] 1.18[0.73; 1.90]Mobarak S (DISCOVER), 2021, Yakoot, 2020276%1,172moderatenot evaluable serious adverse eventsdetailed resultsSadeghi , 2020 1.00 [0.02; 51.94] Yakoot, 2020 1.02 [0.02; 52.72] 1.01[0.06; 16.47]Sadeghi , 2020, Yakoot, 202020%155moderatenot evaluable0.25.01.0relative treatment effectwww.metaEvidence.org2024-04-19 14:24 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 95,94,90,91 - treatments: 815 - roots T: 290